Cited by 262Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismCoenzyme Q10 studies and effects

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia

Mabuchi, Hiroshi, Haba, Toshihiro, Tatami, Ryzo, Miyamoto, Susumu, Sakai, Yasuyuki, Wakasugi, Takanobu, Watanabe, Akira, Koizumi, Junji, Takeda, Ryoyu·1981·New England Journal of Medicine

DOI 10.1056/nejm198108273050902

Open this paper in CoChat — free account

Abstract

We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10-in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 +/- 9 to 303 +/- 8 mg per deciliter (101 +/- 0.2 to 7.88 +/- 0.2 mmol per liter, mean +/- S.E.M.; p less than 0.001) and serum triglyceride decreased from 137 +/- 18 to 87 +/- 9 mg per deciliter (1.55 +/- 0.20 to 0.98 +/- 0.01 mmol per liter; p less than 0.05). Intermediate-density-lipoprotein (DL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (p less than 0.01, P less than 0.001, and P less than 0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 +/- 0.07 to 0.20 +/- 0.01 microgram per milliliter (P less than 0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm198108273050902

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Enzymatic determination of total serum cholesterol.
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,845
THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,737
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
Alberts, A. W., Chen, J., Kuron, G. W., Hunt, V. M., Huff, J. W., Hoffman, C., Rothrock, J. W., López, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,630
Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth.
Brown, M. S., & Goldstein, J. L. (1980) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42221-7 · Cited by 1,210
A colorimetric method for estimating serum triglycerides
Fletcher, M. J. (1968) · Clinica Chimica Acta · doi:10.1016/0009-8981(68)90041-7 · Cited by 1,133
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase
Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38120-6 · Cited by 556

Show all 41 references

Research works printed but not linked: 1

Miettinen, 1974, Eur J Clin Invest, 4, 365

Sorted by citations

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 896
The discovery and development of HMG-CoA reductase inhibitors.
Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 844
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 760
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.13.4124 · Cited by 557
A historical perspective on the discovery of statins
Endo, A. (2010) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.86.484 · Cited by 550
Defective Lipoprotein Receptors and Atherosclerosis
Epstein, F. H., Goldstein, J. L., Kita, T., & Brown, M. S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090507 · Cited by 468
Constituents of Red Yeast Rice, a Traditional Chinese Food and Medicine
Ma, J., Li, Y., Ye, Q., Li, J., Hua, Y., Ju, D., Zhang, D., Cooper, R., & Chang, M. N. T. (2000) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf000338c · Cited by 447
Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.
Ma, P. T. S., Gil, G., Südhof, T. C., Bilheimer, D. W., Goldstein, J. L., & Brown, M. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8370 · Cited by 334
Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Pharmacology of competitive inhibitors of HMg-CoA reductase
Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 275
Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol
Reihnér, E., Rudling, M., Ståhlberg, D., Berglund, L., Ewerth, S., Björkhem, I., Einarsson, K., & Angelin, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230403 · Cited by 277
Biologically active components and nutraceuticals in the Monascus-fermented rice: a review
Lin, Y.-L., Wang, T.-H., Lee, M.-H., & Su, N. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1256-6 · Cited by 262
1 The Discovery and Development of Atorvastatin, A Potent Novel Hypolipidemic Agent
Roth, B. D. (2002) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70080-8 · Cited by 235
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 229
Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia
Havel, R. J., HUNNINGHAKE, D. B., ILLINGWORTH, D. R., Lees, R. S., STEIN, E. A., TOBERT, J. A., BACON, S. R., BOLOGNESE, J. A., FROST, P. H., LAMKIN, G. E., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-609 · Cited by 212
Pathogenesis and Management of Lipoprotein Disorders
Flier, J. S., Underhill, L. H., Schaefer, E. J., & Levy, R. I. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505163122007 · Cited by 213
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Grundy, S. M., & Vega, G. L. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34252-8 · Cited by 208
Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy
Steinberg, D. H. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600009-jlr200 · Cited by 205
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
Tobert, J. A., Bell, G. D., Birtwell, J., James, I. M., Kukovetz, W. R., Pryor, J., Buntinx, A., Holmes, I. B., Chao, Y. S., & Bolognese, J. A. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110530 · Cited by 204
Reduction of Serum Cholesterol in Heterozygous Patients with Familial Hypercholesterolemia
Mabuchi, H., Sakai, T., Sakai, Y., Yoshimura, A., Watanabe, A., WAKASUGI, T., Koizumi, J., & Takeda, R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303173081101 · Cited by 198
Self-citation
Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis
Kim, R. G., Loomba, R., Prokop, L. J., & Singh, S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.039 · Cited by 174
A new grammar for drug discovery
Fishman, M. C., & Porter, J. A. (2005) · Nature · doi:10.1038/437491a · Cited by 193
Pathogenesis and Management of Lipoprotein Disorders
Fredman, S. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603273141310 · Cited by 187
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
Illingworth, D. R., & Sexton, G. J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111618 · Cited by 170
Biosynthesis of Ubiquinone
Olson, R. E., & Rudney, H. (1983) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60431-8 · Cited by 165
Xanthomas and hyperlipidemias
Parker, F. S. (1985) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(85)70139-9 · Cited by 166
Lovastatin for Lowering Cholesterol Levels in Non-Insulin-Dependent Diabetes Mellitus
Garg, A., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180204 · Cited by 158
EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIA
Mol, M. J. T. M., Leuven, J. A. G., Erkelens, D. W., Schouten, T. A., & Stalenhoef, A. F. H. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90598-2 · Cited by 156
A gift from nature: the birth of the statins
Endo, A. (2008) · Nature Medicine · doi:10.1038/nm1008-1050 · Cited by 152
Lowering Plasma Cholesterol by Raising LDL Receptors
Brown, M. S., & Goldstein, J. L. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050909 · Cited by 142
Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia
Illingworth, D. R. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-5-598 · Cited by 129
Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Maltese, W. A., Defendini, R., Green, R. A., Sheridan, K. M., & Donley, D. K. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112165 · Cited by 125
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
Grundy, S. M., & Bilheimer, D. W. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.8.2538 · Cited by 123
The synthesis of mevinic acids
Rosen, T., & Heathcock, C. H. (1986) · Tetrahedron · doi:10.1016/s0040-4020(01)88045-5 · Cited by 120
Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 119
Self-citation
3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia.
Hoeg, J. M., & Brewer, H. B. (1987) · PubMed · Cited by 118
Combination Drug Therapy for Familial Combined Hyperlipidemia
East, C. A., Bilheimer, D. W., & Grundy, S. M. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-1-25 · Cited by 118
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Jamal, S. M., Eisenberg, M. J., & Christopoulos, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.037 · Cited by 111
Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.
Watts, G. F., Castelluccio, C., Rice-Evans, C. A., Taub, N. A., Baum, H., & Quinn, P. J. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.11.1055 · Cited by 109
Statin use is associated with lower disease severity in COVID-19 infection
Tan, W. Y. T., Young, B. E., Lye, D. C., Chew, D. E. K., & Dalan, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74492-0 · Cited by 107
Influence of Combined Therapy with Mevinolin and Interruption of Bile-Acid Reabsorption on Low Density Lipoproteins in Heterozygous Familial Hypercholesterolemia
Grundy, S. M., Vega, G. L., & Bilheimer, D. W. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-3-339 · Cited by 106
Mode of interaction of .beta.-hydroxy-.beta.-methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds
Nakamura, C. E., & Abeles, R. H. (1985) · Biochemistry · doi:10.1021/bi00327a014 · Cited by 105
Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber.
Endo, A., Hasumi, K., & Negishi, S. (1985) · The Journal of Antibiotics · doi:10.7164/antibiotics.38.420 · Cited by 103
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley, S. T., Kalinowski, S. S., Schafer, B. L., & Tanaka, R. D. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38255-9 · Cited by 103
Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Mabuchi, H. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16008 · Cited by 102
Self-citation
Analysis of five HMG‐CoA reductase inhibitors— atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies
Pasha, M. K., Syed, M., Shaik, J. S., Shashikumar, D., Mullangi, R., & Srinivas, N. R. (2005) · Biomedical Chromatography · doi:10.1002/bmc.561 · Cited by 100
Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers.
Singer, I. I., Kawka, D. W., Kazazis, D. M., Alberts, A. W., Chen, J. S., Huff, J. W., & Ness, G. C. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.17.5556 · Cited by 99
Influence of probucol on cholesterol and lipoprotein metabolism in man.
Kesäniemi, Y. A., & Grundy, S. M. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37741-5 · Cited by 96
Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors
Laaksonen, R., Ojala, J.-P., Tikkanen, M. J., & Himberg, J. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00194398 · Cited by 94
Mevastatin inhibits ovarian theca–interstitial cell proliferation and steroidogenesis
Izquierdo, D. M., Foyouzi, N., Kwintkiewicz, J., & Dulęba, A. J. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.03.037 · Cited by 90
Update on statin-mediated anti-inflammatory activities in atherosclerosis
Montecucco, F., & Mach, F. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0150-y · Cited by 91
Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia
Malloy, M. J., KANE, J. P., KUNITAKE, S. T., & TUN, P. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-5-616 · Cited by 87
Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma
Berthold, H. K., Naini, A., Mauro, S. D., Hallikainen, M., Gylling, H. K., Krone, W., & Gouni‐Berthold, I. (2006) · Drug Safety · doi:10.2165/00002018-200629080-00007 · Cited by 87
Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia
Hoeg, J. M., Maher, M. B., Zech, L. A., Bailey, K. R., Gregg, R. E., Lackner, K. J., Fojo, S. S., Anchors, M., Bojanovski, M., Sprecher, D. L., et al. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90733-2 · Cited by 82
Ubiquinone biosynthesis in Saccharomyces cerevisiae. Isolation and sequence of COQ3, the 3,4-dihydroxy-5-hexaprenylbenzoate methyltransferase gene.
Clarke, C. F., Williams, W., & Teruya, J. H. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55349-7 · Cited by 81
The Effect of CS-514 on Serum Lipids and Apolipoproteins in Hypercholesterolemic Subjects
Nakaya, N. (1987) · JAMA · doi:10.1001/jama.1987.03390220086026 · Cited by 81
Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia
Mol, M. J. T. M., Erkelens, D. W., Leuven, J. A. G., Schouten, J. A., & Stalenhoef, A. F. H. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90006-8 · Cited by 79
Peripheral neuropathy associated with simvastatin.
Phan, T. G., McLeod, J. G., Pollard, J. D., Peiris, O. A., Rohan, A., & Halpern, J. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.5.625 · Cited by 77
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Suppression of principal atherosclerotic mechanisms by prostacyclinc and other eicosanoids
Willis, A. L., Smith, D. L., & Vigo, C. (1986) · Progress in Lipid Research · doi:10.1016/0163-7827(86)90132-3 · Cited by 76
Statins—From Fungi to Pharmacy
Sadowska, A. J., Osiński, P., Roztocka, A., Kaczmarz-Chojnacka, K., Zapora, E., Sawicka, D., & Car, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010466 · Cited by 83
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
Elmberger, P. G., Kalén, A., Lund, E. G., Reihnér, E., Eriksson, M., Berglund, L., Angelin, B., & Dallner, G. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41990-x · Cited by 72
An Approach to the Management of Hyperlipoproteinemia
Hoeg, J. M. (1986) · JAMA · doi:10.1001/jama.1986.03370040086030 · Cited by 71
Impact of Statin Treatment on the Clinical Fate of Heterozygous Familial Hypercholesterolemia
Harada-Shiba, M., Sugisawa, T., Makino, H., Abe, M., Tsushima, M., Yoshimasa, Y., Yamashita, T., Miyamoto, Y., Yamamoto, A., Tomoike, H., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.4143 · Cited by 70
Metabolic modes of action of the statins in the hyperlipoproteinemias
Aguilar-Salinas, C. A., Barrett, P. H. R., & Schonfeld, G. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00198-1 · Cited by 70
Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples
Toker, S. E., Önal, A., & Çetin, S. M. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00314-3 · Cited by 69
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors
Bargossi, A., Grossi, G., Fiorella, P. L., Gaddi, A. V., Giulio, R. D., & Battino, M. A. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90028-0 · Cited by 69
Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
Bargossi, A., Battino, M. A., Gaddi, A. V., Fiorella, P. L., Grossi, G., Barozzi, G., Giulio, R. D., Descovich, G. C., Sassi, S., Genova, M. L., et al. (1994) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592449 · Cited by 69
HMG-CoA reductase inhibitors
Endo, A., & Hasumi, K. (1993) · Natural Product Reports · doi:10.1039/np9931000541 · Cited by 68
Statins: Past and Present
Hajar, R. (2011) · Heart Views · doi:10.4103/1995-705x.95070 · Cited by 67
Lipid lowering agents of natural origin: An account of some promising chemotypes
Singh, S. P., & Sashidhara, K. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.020 · Cited by 67
LOVASTATIN, ISOPRENES, AND MYOPATHY
Walravens, P., Greene, C. L., & Frerman, F. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91108-2 · Cited by 66
Screening Asymptomatic Adults for Cardiac Risk Factors: The Serum Cholesterol Level
Garber, A. M., Sox, H. C., & Littenberg, B. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-8-622 · Cited by 63
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia
Illingworth, D. R., & Bacon, S. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90589-3 · Cited by 62
CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
van der Ende, E. L., Veld, S. G. J. G. I. ‘., Hanskamp, I., van der Lee, S. J., Dijkstra, J. I. R., Hok‐A‐Hin, Y. S., Blujdea, E. R., Swieten, J. C. V., Irwin, D. J., Chen‐Plotkin, A. S., et al. (2023) · Brain · doi:10.1093/brain/awad213 · Cited by 59
Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors
Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 60
Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet
Chao, Y., Kroon, P. A., Yamin, T.-T., Thompson, G. M., & Alberts, A. W. (1983) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(83)90154-6 · Cited by 55
Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects.
Stone, B. G., Evans, C. D., Prigge, W. F., Duane, W. C., & Gebhard, R. L. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38206-7 · Cited by 53
Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells.
Maltese, W. A., & Aprille, J. R. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39062-2 · Cited by 53
Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia
Mabuchi, H., KAMON, N., Fujita, H., Michishita, I., TAKEDA, M., Kajinami, K., Itoh, H., WAKASUGI, T., & Takeda, R. (1987) · Metabolism · doi:10.1016/0026-0495(87)90046-1 · Cited by 53
Self-citation
Lovastatin in the Treatment of Multifactorial Hyperlipidemia Associated With Proteinuria
Golper, T. A., Illingworth, D. R., Morris, C. D., & Bennett, W. M. (1989) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(89)80038-1 · Cited by 53
Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.
Uusitupa, M. I. J., Miettinen, T. A., Happonen, P., Ebeling, T., Turtola, H., Voutilainen, E., & Pyörälà, K. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.7.807 · Cited by 52
Inhibition of cholesterol synthesis by ketoconazole
Kraemer, F. B., & Pont, A. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90816-8 · Cited by 50
Genome‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records
Robinson, J. R., Denny, J. C., Roden, D. M., & Driest, S. L. V. (2017) · Clinical and Translational Science · doi:10.1111/cts.12522 · Cited by 51
Intracellular tPA–PAI-1 interaction determines VLDL assembly in hepatocytes
Dai, W., Zhang, H., Lund, H., Zhang, Z., Castleberry, M., Rodriguez, M., Kuriakose, G., Gupta, S. K., Lewandowska, M., Powers, H. R., et al. (2023) · Science · doi:10.1126/science.adh5207 · Cited by 52
Simvastatin: A Review of its Pharmacology and Clinical Use
Mauro, V. F., & MacDonald, J. L. (1991) · DICP · doi:10.1177/106002809102500309 · Cited by 47
The Effect of CS-514, an Inhibitor of HMG-CoA Reductase, on Serum Lipids in Healthy Volunteers
Nakaya, N., Homma, Y., TAMACHI, H., & Goto, Y. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90071-7 · Cited by 47
Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia
Pappu, A. S., Illingworth, D. R., & Bacon, S. (1989) · Metabolism · doi:10.1016/0026-0495(89)90214-x · Cited by 44
HMG-CoA reductase inhibitors
Illingworth, D. R., & Tobert, J. A. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56003-9 · Cited by 43
Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women
Markowska, A., Antoszczak, M., Markowska, J., & Huczyński, A. (2020) · Pharmaceuticals · doi:10.3390/ph13120422 · Cited by 45
Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat
Lőw, P., Andersson, M., Edlund, C., & Dallner, G. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90081-6 · Cited by 41
COMPARISON BETWEEN SIMVASTATIN AND BEZAFIBRATE IN EFFECT ON PLASMA LIPOPROTEINS AND APOLIPOPROTEINS IN PRIMARY HYPERCHOLESTEROLAEMIA
Schulzeck, P., Jochim, A., Bojanovski, M., Canzler, H., & Bojanovski, D. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91414-6 · Cited by 42
Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression
Cleland, J. G. F., & McGowan, J. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199906003-00003 · Cited by 42
A tribute to Akira Endo, discoverer of a “Penicillin” for cholesterol
Brown, M. S., & Goldstein, J. L. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.007 · Cited by 41

Authors: Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R.
Affiliations: Kanazawa University (JP)
ORCID: Miyamoto, Susumu
Sakai, Yasuyuki
Watanabe, Akira
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1981-08-27
Volume: 305
Issue: 9
Pages: 478-482
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm198108273050902
OpenAlex: W2051105453
Cited by: 262
References: 41
Citations by year: 2025: 2 · 2024: 6 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 2 · 2012: 2
FWCI: 25.89
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Keywords: ML-236B, statins, familial hypercholesterolemia, serum cholesterol, serum triglycerides, lipoproteins, LDL cholesterol, intermediate density lipoprotein, ubiquinone-10
MeSH terms: Adult, Aged, Cholesterol, Female, Heterozygote, Humans, Hyperlipoproteinemia Type II, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Lovastatin, Male, Middle Aged, Naphthalenes, Triglycerides, Ubiquinone, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks